Literature DB >> 9725263

Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.

W R Drobyski1, D Majewski, K Ozker, G Hanson.   

Abstract

The purpose of this study was to determine whether ex vivo anti-CD3 Ab-activated T cells behaved in a biologically similar manner as naive T cells with respect to causing graft-vs-host disease (GVHD) and facilitating engraftment after allogeneic marrow transplantation. This question was addressed using two well-defined MHC-incompatible murine models of GVHD (C57BL/6 (H-2b)-->BIO.BR (H-2k)) and engraftment (C57BL/6 (H-2b)-->AKR/J (H-2k)). Transplantation with anti-CD3-activated T cells significantly reduced GVHD compared with that in animals transplanted with equivalent numbers of naive T cells. Protection from GVHD was not T cell subset dependent, as highly enriched populations of either activated CD4+ or CD8+ T cells caused less lethal GVHD than comparable numbers of purified naive CD4+ or CD8+ T cells. Transplantation with activated T cells also resulted in protection from LPS-mediated GVH lethality in unirradiated F1 recipients. Analysis of immune recovery indicated that animals transplanted with activated T cells had thymic and splenic B cell reconstitution that compared favorably to that in non-GVHD control mice. When engraftment was analyzed, equivalent degrees of donor cell engraftment were observed when animals were transplanted with limiting numbers (5 x 10(5)) of naive vs activated B6 T cells. Further studies indicated that activated CD8+ T cells were exclusively responsible for enhancing engraftment and that facilitation of engraftment was dependent upon the direct recognition of host MHC alloantigens. Collectively, these data demonstrate that transplantation with anti-CD3 Ab-activated T cells results in a reduction in GVHD, but these cells retain their ability to facilitate alloengraftment. The use of this approach in allogeneic marrow transplantation may represent an alternative strategy to mitigate GVHD without compromising engraftment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725263

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Authors:  Lawrence G Lum; Mayur Ramesh; Archana Thakur; Subhashis Mitra; Abhinav Deol; Joseph P Uberti; Philip E Pellett
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-05       Impact factor: 5.742

2.  Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.

Authors:  K Mizrahi; I Yaniv; S Ash; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

Review 3.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Jian-Ming Li; Cynthia R Giver; Ying Lu; Mohammad S Hossain; Mojtaba Akhtari; Edmund K Waller
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

4.  Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection.

Authors:  Sanja Vodanovic-Jankovic; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2006-11       Impact factor: 5.742

5.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Authors:  Bruno Nervi; Michael P Rettig; Julie K Ritchey; Hanlin L Wang; Gerhard Bauer; Jon Walker; Mark L Bonyhadi; Ronald J Berenson; Julie L Prior; David Piwnica-Worms; Jan A Nolta; John F DiPersio
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

6.  In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.

Authors:  J K Orleans-Lindsay; A Deru; J I O Craig; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

7.  Outgrowth of CD4low/negCD25+ T cells with suppressor function in CD4+CD25+ T cell cultures upon polyclonal stimulation ex vivo.

Authors:  Christine Vogtenhuber; Matthew J O'Shaughnessy; Dario A A Vignali; Bruce R Blazar
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

8.  Evaluation of the tolerogenic effects of donor bone marrow cells using a severe combined immunodeficient mouse-human islet transplant model.

Authors:  James M Mathew; Bonnie Blomberg; Camillo Ricordi; Violet Esquenazi; Joshua Miller
Journal:  Hum Immunol       Date:  2008-08-12       Impact factor: 2.850

Review 9.  Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.

Authors:  Michael R Verneris; Jeanette Baker; Matthias Edinger; Robert S Negrin
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

10.  Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Authors:  Nicolas Montcuquet; Patricia Mercier-Letondal; Sylvain Perruche; Anne Duperrier; Mélanie Couturier; Abdelghani Bouchekioua; Mark Bonyhadi; Christophe Ferrand; Pierre Tiberghien; Eric Robinet
Journal:  Immunology       Date:  2008-04-26       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.